The most advanced is ISB 1342, a first-generation bispecific antibody targeting both cluster of differentiation 38 (CD38) on myeloma cells and CD3 on T cells, which is in phase 1 testing for ...

a bispecific antibody that binds to CD3 and GPRC5D, a novel myeloma target. Both bispecifics have arisen out of J&J's longstanding alliance with Genmab, which also generated anti-CD38 blockbuster ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

Tecvayli (teclistamab) is an off-the-shelf bispecific antibody targeting both BCMA and CD3 which is also under ... an antibody directed at CD38 – and BCMA-targeted CAR-T therapy Carvykti ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...